MNG1219
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.360
- MYC_TARGETS_V2+0.328
- TGF_BETA_SIGNALING+0.283
- UNFOLDED_PROTEIN_RESPONSE+0.262
- UV_RESPONSE_DN+0.224
- E2F_TARGETS+0.223
- PROTEIN_SECRETION+0.212
- G2M_CHECKPOINT+0.201
- TNFA_SIGNALING_VIA_NFKB+0.149
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.144
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.377
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.340
- ANGIOGENESIS-0.301
- GLYCOLYSIS-0.275
- SPERMATOGENESIS-0.209
- ESTROGEN_RESPONSE_LATE-0.208
- KRAS_SIGNALING_DN-0.197
- HEDGEHOG_SIGNALING-0.184
- MYOGENESIS-0.177
- ESTROGEN_RESPONSE_EARLY-0.162
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG951 | — | — | 0.753 |
| 2 | MDT-AP-3050 | Med | Medulloblastoma | 0.731 |
| 3 | MNG240 | — | — | 0.720 |
| 4 | SRR934914 | — | — | 0.707 |
| 5 | SRR1516083 | — | — | 0.704 |
| 6 | R193 | — | — | 0.702 |
| 7 | SRR934930 | — | — | 0.701 |
| 8 | SRR934950 | — | — | 0.700 |
| 9 | 8B2B5542-3E54-4643-BB57-0BEFCF89A16B | — | — | 0.698 |
| 10 | SRR934775 | — | — | 0.695 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.360 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.328 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.283 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.262 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.224 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.223 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.212 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.201 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.149 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.144 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.135 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.133 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.124 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.114 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.098 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.090 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.080 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.068 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.067 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.062 | Remibrutinib | — uncovered |